Shamburg News · 8-K filed Nov 12, 2026, 4:05 PM EST

Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Updates

ASMB · ASSEMBLY BIOSCIENCES, INC.

  • Earnings
  • Materiality: high

Assembly Biosciences reported a net loss attributable to common stockholders of $20.3 million, or $0.93 per basic and diluted share, for the quarter ended September 30, 2026, compared with $9.2 million, or $0.72 per share, a year earlier. Collaboration revenue from Gilead was $3.0 million, compared with $10.8 million in the prior-year quarter, and research and development expenses rose to $20.2 million. Cash, cash equivalents and marketable securities totaled $314.3 million at September 30, 2026, and the company received a $75 million collaboration extension fee from Gilead in November 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458314.

Written from the filing by Shamburg Markets. Figures are as reported by the company.